Regeneron, Sanofi announce Dupixent outperformed Xolair

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) presented positive results from the EVEREST Phase 4 trial in adults with severe chronic rhinosinusitis with nasal polyps and coexisting asthma. In the trial, Dupixent outperformed Xolair on all primary and secondary efficacy endpoints of CRSwNP, and in all asthma-related endpoints. The data are from the first-ever presented head-to-head respiratory trial with biologic medicines and were shared in a late-breaking oral presentation at the 2025 European Academy of Allergy and Clinical Immunology, EAACI, Annual Congress. Results reinforce the efficacy of Dupixent in treating both upper and lower respiratory diseases by targeting IL-4 and IL-13, two key drivers of type 2 inflammation